Sulindac enhances the effectiveness of anti-PD-L1 therapy for colorectal cancer
Sulindac sensitizes colorectal cancer to anti-PD-L1 therapy
This study is looking at whether adding a low dose of the drug sulindac can help make immunotherapy work better for people with colorectal cancer who usually don’t respond to current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-10909401 on NIH RePORTER |
What this research studies
This research investigates how the drug sulindac can improve the effectiveness of anti-PD-L1 therapy in patients with colorectal cancer who typically do not respond to current immunotherapies. The study uses mouse models to explore the combination of low-dose sulindac and PD-L1 antibodies, aiming to increase the immune response against tumors. By examining changes in tumor size and immune cell activity, the research seeks to identify a new treatment strategy for patients with proficient mismatch repair colorectal cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with proficient mismatch repair (pMMR) and microsatellite stable (MSS) colorectal cancer.
Not a fit: Patients with deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for colorectal cancer patients who currently have limited therapeutic choices.
How similar studies have performed: Preliminary studies have shown promising results with similar approaches, indicating potential for success in this area.
Where this research is happening
Athens, United States
- University of Georgia — Athens, United States (Active)
Researchers
- Principal investigator: Xi, Yaguang — University of Georgia
- Study coordinator: Xi, Yaguang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.